Atara Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atara Biotherapeutics, Inc. on August 10, 2021, reporting events occurring on August 9, 2021. The filing addresses corporate governance changes specifically regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Ameet Mallik to the Board of Directors to fill a vacant seat. His initial term expires at the 2024 annual meeting of stockholders. The Board determined Mr. Mallik is independent under applicable SEC requirements and Nasdaq listing standards.
Compensation and Governance Details
- Role: Independent Director (no standing committee assignments).
- Annual Retainer: $45,000, pro-rated for partial periods of service starting August 9, 2021.
- Equity Grant: Option to purchase 55,000 shares of Common Stock, vesting annually over three years subject to continuous service.
- Agreements: Standard form of indemnification agreement executed.
Investor Verification Checklist
- Verify the independence status of Ameet Mallik against the company's Corporate Governance Guidelines.
- Review the 2021 Proxy Statement (filed April 22, 2021) for full details on non-employee director compensation structures.
- Confirm the vesting schedule and exercise terms of the 55,000 share option grant.
- Check for any subsequent filings regarding committee assignments for the new director.